Deciphex, a Dublin, Ireland-based provider of pathology software and services, raised €3.9M in funding.
The round was led by Seroba Life Sciences and existing investors. Jennifer McMahon, a partner with Seroba, will join the Board of Deciphex.
The company intends to use the funds to continue developing its products and services, to expand its presence in the UK, Canada, the Middle East and the US, and to strengthen its position in the field of digital pathology and AI.
Led by CEO Donal O’Shea, Deciphex offers a range of services for clinical and research pathology, including its Patholytix platform for research pathology. Its Diagnostics as a service platform, Diagnexia, connects laboratories to an international network of subspeciality pathologists, who can provide their expertise on clinical cases, while reducing turnaround times and ensuring the delivery of the highest quality of patient care.
Commenting on the news, Donal O’Shea said: “This additional investment will allow us to continue to grow and innovate, solidifying our position as a leader in the field of pathology. We are committed to helping pathologists deliver the best possible care to patients through the use of cutting-edge technology.“
FinSMEs
23/01/2023